<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39359976</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-0849</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>JACC. Case reports</Title><ISOAbbreviation>JACC Case Rep</ISOAbbreviation></Journal><ArticleTitle>Eosinophilic Endomyocarditis After COVID-19 Infection in a Heart Transplant Recipient.</ArticleTitle><Pagination><StartPage>102527</StartPage><MedlinePgn>102527</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102527</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccas.2024.102527</ELocationID><Abstract><AbstractText>Eosinophilic myocarditis (EM) is a rare cause of heart failure, with high in-hospital mortality associated with fulminant disease. A 61-year-old female transplant recipient was diagnosed with COVID-19 after presenting with 2 days of constitutional symptoms. She developed acute heart failure from EM. After an initial response to inotropic support and corticosteroids, she had a relapse with de novo peripheral eosinophilia which responded to further eosinophilic myocarditis management and the addition of mepolizumab. Although there have been reports after COVID-19 vaccination, association with active SARS-CoV-2 infection is rare. This paper reports, for the first time, the case of a heart transplant recipient with EM after COVID-19.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Inglis</LastName><ForeName>Sara S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Anshul R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexandrino</LastName><ForeName>Francisco B</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aubry</LastName><ForeName>Marie C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Leslie T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anavekar</LastName><ForeName>Nandan S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behfar</LastName><ForeName>Atta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunlay</LastName><ForeName>Shannon M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jentzer</LastName><ForeName>Jacob C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>daSilva-deAbreu</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JACC Case Rep</MedlineTA><NlmUniqueID>101757292</NlmUniqueID><ISSNLinking>2666-0849</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">eosinophilic myocarditis</Keyword><Keyword MajorTopicYN="N">heart transplantation</Keyword></KeywordList><CoiStatement>The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39359976</ArticleId><ArticleId IdType="pmc">PMC11442253</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2024.102527</ArticleId><ArticleId IdType="pii">S2666-0849(24)00396-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abete R., Valastro P., Iacovoni A., et al. Acute necrotizing eosinophilic myocarditis presenting with cardiogenic shock after mRNA booster dose for COVID-19: Case report and review of literature. J Cardiol Cases. 2023;27:52–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9911929</ArticleId><ArticleId IdType="pubmed">36788951</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoateng R., Noory A., Raina A., Lander M. A rare case of eosinophilic myocarditis due to subacute SARS-CoV-2 illness. J Card Fail. 2023;29:576–577.</Citation></Reference><Reference><Citation>Craver R., Huber S., Sandomirsky M., McKenna D., Schieffelin J., Finger L. Fatal eosinophilic myocarditis in a healthy 17-year-old male with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2c) Fetal Pediatr Pathol. 2020;39:263–268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7232882</ArticleId><ArticleId IdType="pubmed">32401577</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambatti M., Matassini M.V., Adler E.D., Klingel K., Camici P.G., Ammirati E. Eosinophilic myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol. 2017;70:2363–2375.</Citation><ArticleIdList><ArticleId IdType="pubmed">29096807</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway J., Wilson G.J., Dipchand A.I. A fatal case with eosinophilia after pediatric heart transplantation. J Hear Lung Transplant. 2011;30:596–599.</Citation><ArticleIdList><ArticleId IdType="pubmed">21414806</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdou M.H., Hadi M.A., Brittsan A., Caccamo M.A. De novo eosinophilic myocarditis after heart transplantation. Arch Transplant. 2017;1:1–3.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>